0001209191-20-045935.txt : 20200810
0001209191-20-045935.hdr.sgml : 20200810
20200810161944
ACCESSION NUMBER: 0001209191-20-045935
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200806
FILED AS OF DATE: 20200810
DATE AS OF CHANGE: 20200810
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kewalramani Reshma
CENTRAL INDEX KEY: 0001735944
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 201089633
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS, INC.
STREET 2: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-08-06
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001735944
Kewalramani Reshma
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
1
1
0
0
CEO & President
Common Stock
2020-08-06
4
M
0
1564
187.53
A
28190
D
Common Stock
2020-08-06
4
M
0
509
155.57
A
28699
D
Common Stock
2020-08-06
4
S
0
152
269.11
D
28547
D
Common Stock
2020-08-06
4
S
0
870
270.36
D
27677
D
Common Stock
2020-08-06
4
S
0
471
271.42
D
27206
D
Common Stock
2020-08-06
4
S
0
487
272.76
D
26719
D
Common Stock
2020-08-06
4
S
0
93
273.27
D
26626
D
Stock Option (Right to Buy)
187.53
2020-08-06
4
M
0
1564
0.00
D
2029-02-05
Common Stock
1564
15642
D
Stock Option (Right to Buy)
155.57
2020-08-06
4
M
0
509
0.00
D
2028-02-05
Common Stock
509
3058
D
Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $269.11 (range $268.69 to $269.59).
Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $270.36 (range $269.90 to $270.85).
Open market sales reported on this line occurred at a weighted average price of $271.42 (range $270.97 to $271.88).
Open market sales reported on this line occurred at a weighted average price of $272.76 (range $272.25 to $272.99).
The option vests in 16 quarterly installments from 02/06/2019.
The option vests in 16 quarterly installments from 02/06/2018.
/s/ Sabrina Yohai, Attorney-in-Fact
2020-08-10